Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR
PURPOSE To compare the outcomes of patients with Hodgkin or non-Hodgkin lymphoma undergoing nonmyeloablative haploidentical or unrelated cord blood (UCB) hematopoietic cell transplantation. PATIENTS AND METHODS We retrospectively studied 740 patients with Hodgkin lymphoma (n = 283, 38%) and non-Hodg...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2020-05, Vol.38 (14), p.1518-1526 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1526 |
|---|---|
| container_issue | 14 |
| container_start_page | 1518 |
| container_title | Journal of clinical oncology |
| container_volume | 38 |
| creator | Fatobene, Giancarlo Rocha, Vanderson St Martin, Andrew Hamadani, Mehdi Robinson, Stephen Bashey, Asad Boumendil, Ariane Brunstein, Claudio Castagna, Luca Dominietto, Alida Finel, Herve Chalandon, Yves Kenzey, Chantal Kharfan-Dabaja, Mohamed Labussiere-Wallet, Helene Moraleda, Jose M. Pastano, Rocco Perales, Miguel-Angel El Ayoubi, Hanadi Rafii Ruggeri, Annalisa Sureda, Anna Volt, Fernanda Yakoub-Agha, Ibrahim Zhang, Mei-Jie Gluckman, Eliane Montoto, Silvia Eapen, Mary |
| description | PURPOSE To compare the outcomes of patients with Hodgkin or non-Hodgkin lymphoma undergoing nonmyeloablative haploidentical or unrelated cord blood (UCB) hematopoietic cell transplantation.
PATIENTS AND METHODS We retrospectively studied 740 patients with Hodgkin lymphoma (n = 283, 38%) and non-Hodgkin lymphoma (n = 457, 62%) age 18-75 years who received transplantations from 2009 to 2016. Data were reported to the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, Eurocord, or Center for International Blood and Marrow Transplant Research. Of the 526 patients who received haploidentical transplantation, 68% received bone marrow and 32% received peripheral blood. All patients received a uniform transplantation conditioning regimen (2 Gy of total-body irradiation, cyclophosphamide, and fludarabine) and graft-versus-host disease prophylaxis (calcineurin inhibitor and mycophenolate). In addition, patients who received a haploidentical transplantation received posttransplantation cyclophosphamide.
RESULTS Compared with haploidentical bone marrow and peripheral-blood transplantations and adjusted for age, lymphoma subtype, and disease status, survival was lower after UCB transplantation (hazard ratio [HR], 1.55; P = .001; and HR, 1.59; P = .005, respectively). Similarly, progression-free survival was lower after UCB transplantations compared with haploidentical bone marrow and peripheral-blood transplantations (HR, 1.44; P = .002; and HR, 1.86; P < .0001), respectively. The 4-year overall and progression-free survival rates after UCB transplantation were 49% and 36%, respectively, compared with 58% and 46% after haploidentical bone marrow transplantation and 59% and 52% after peripheral-blood transplantation, respectively. Lower survival was attributed to higher transplantation-related mortality after UCB transplantation compared with haploidentical bone marrow and peripheral-blood transplantation (HR, 1.91; P = .0001; and HR, 2.27; P = .0002, respectively).
CONCLUSION When considering HLA-mismatched transplantation for Hodgkin or non-Hodgkin lymphoma, the data support haploidentical related donor transplantation over UCB transplantation. |
| doi_str_mv | 10.1200/JCO.19.02408 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_000537768800003CitationCount</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2352646945</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-a0d7fc36a905be3b6dedc1e5abcc66d69d918361a381409432ada623222928303</originalsourceid><addsrcrecordid>eNqNkc1v1DAQxS1ERZfCjTPKEYnNMrZjJ-aAVML2Ay0UoUVwsxzH6YYm9mInRXvjT6_btCu4cfL4-TdvbD-EXmBYYALw5mN5scBiASSD4hGaYUbyNM8Ze4xmkFOS4oL-OERPQ_gJgLOCsifokBKguMj5DP357Gy_M51TVaeG9tokx91gvJ3qD846n6y9smHbKTtE1dmkidqZqy-vWpsoWyfRIn3Yr3b9duN69TY58a5Pho1JVt-_pMv3n9bzZDl6p52v53dt5XkUvz5DB43qgnl-vx6hbyfLdXmWri5Oz8vjVaozBkOqoM4bTbkSwCpDK16bWmPDVKU15zUXtYgP5VjRAmcgMkpUrTihhBBBCgr0CL2bfLdj1cdeYwevOrn1ba_8TjrVyn9PbLuRl-5a5gRTJnA0eHVv4N2v0YRB9m3Qpov_YtwYJKGM8IyLjEV0PqHauxC8afZjMMjb0GQMTWIh70KL-Mu_r7aHH1KKwOsJ-G0q1wTdGqvNHgMARvOcF0WsgEa6-H-6bKdQSzfagd4Art6zsQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2352646945</pqid></control><display><type>article</type><title>Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR</title><source>American Society of Clinical Oncology Online Journals</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Fatobene, Giancarlo ; Rocha, Vanderson ; St Martin, Andrew ; Hamadani, Mehdi ; Robinson, Stephen ; Bashey, Asad ; Boumendil, Ariane ; Brunstein, Claudio ; Castagna, Luca ; Dominietto, Alida ; Finel, Herve ; Chalandon, Yves ; Kenzey, Chantal ; Kharfan-Dabaja, Mohamed ; Labussiere-Wallet, Helene ; Moraleda, Jose M. ; Pastano, Rocco ; Perales, Miguel-Angel ; El Ayoubi, Hanadi Rafii ; Ruggeri, Annalisa ; Sureda, Anna ; Volt, Fernanda ; Yakoub-Agha, Ibrahim ; Zhang, Mei-Jie ; Gluckman, Eliane ; Montoto, Silvia ; Eapen, Mary</creator><creatorcontrib>Fatobene, Giancarlo ; Rocha, Vanderson ; St Martin, Andrew ; Hamadani, Mehdi ; Robinson, Stephen ; Bashey, Asad ; Boumendil, Ariane ; Brunstein, Claudio ; Castagna, Luca ; Dominietto, Alida ; Finel, Herve ; Chalandon, Yves ; Kenzey, Chantal ; Kharfan-Dabaja, Mohamed ; Labussiere-Wallet, Helene ; Moraleda, Jose M. ; Pastano, Rocco ; Perales, Miguel-Angel ; El Ayoubi, Hanadi Rafii ; Ruggeri, Annalisa ; Sureda, Anna ; Volt, Fernanda ; Yakoub-Agha, Ibrahim ; Zhang, Mei-Jie ; Gluckman, Eliane ; Montoto, Silvia ; Eapen, Mary</creatorcontrib><description>PURPOSE To compare the outcomes of patients with Hodgkin or non-Hodgkin lymphoma undergoing nonmyeloablative haploidentical or unrelated cord blood (UCB) hematopoietic cell transplantation.
PATIENTS AND METHODS We retrospectively studied 740 patients with Hodgkin lymphoma (n = 283, 38%) and non-Hodgkin lymphoma (n = 457, 62%) age 18-75 years who received transplantations from 2009 to 2016. Data were reported to the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, Eurocord, or Center for International Blood and Marrow Transplant Research. Of the 526 patients who received haploidentical transplantation, 68% received bone marrow and 32% received peripheral blood. All patients received a uniform transplantation conditioning regimen (2 Gy of total-body irradiation, cyclophosphamide, and fludarabine) and graft-versus-host disease prophylaxis (calcineurin inhibitor and mycophenolate). In addition, patients who received a haploidentical transplantation received posttransplantation cyclophosphamide.
RESULTS Compared with haploidentical bone marrow and peripheral-blood transplantations and adjusted for age, lymphoma subtype, and disease status, survival was lower after UCB transplantation (hazard ratio [HR], 1.55; P = .001; and HR, 1.59; P = .005, respectively). Similarly, progression-free survival was lower after UCB transplantations compared with haploidentical bone marrow and peripheral-blood transplantations (HR, 1.44; P = .002; and HR, 1.86; P < .0001), respectively. The 4-year overall and progression-free survival rates after UCB transplantation were 49% and 36%, respectively, compared with 58% and 46% after haploidentical bone marrow transplantation and 59% and 52% after peripheral-blood transplantation, respectively. Lower survival was attributed to higher transplantation-related mortality after UCB transplantation compared with haploidentical bone marrow and peripheral-blood transplantation (HR, 1.91; P = .0001; and HR, 2.27; P = .0002, respectively).
CONCLUSION When considering HLA-mismatched transplantation for Hodgkin or non-Hodgkin lymphoma, the data support haploidentical related donor transplantation over UCB transplantation.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.19.02408</identifier><identifier>PMID: 32031876</identifier><language>eng</language><publisher>ALEXANDRIA: Amer Soc Clinical Oncology</publisher><subject>Life Sciences & Biomedicine ; Oncology ; ORIGINAL REPORTS ; Science & Technology</subject><ispartof>Journal of clinical oncology, 2020-05, Vol.38 (14), p.1518-1526</ispartof><rights>2020 by American Society of Clinical Oncology 2020 American Society of Clinical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>32</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000537768800003</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c450t-a0d7fc36a905be3b6dedc1e5abcc66d69d918361a381409432ada623222928303</citedby><cites>FETCH-LOGICAL-c450t-a0d7fc36a905be3b6dedc1e5abcc66d69d918361a381409432ada623222928303</cites><orcidid>0000-0002-2552-0542 ; 0000-0002-6239-7387 ; 0000-0002-3006-9725</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,781,785,886,3730,27929,27930,28253</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32031876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fatobene, Giancarlo</creatorcontrib><creatorcontrib>Rocha, Vanderson</creatorcontrib><creatorcontrib>St Martin, Andrew</creatorcontrib><creatorcontrib>Hamadani, Mehdi</creatorcontrib><creatorcontrib>Robinson, Stephen</creatorcontrib><creatorcontrib>Bashey, Asad</creatorcontrib><creatorcontrib>Boumendil, Ariane</creatorcontrib><creatorcontrib>Brunstein, Claudio</creatorcontrib><creatorcontrib>Castagna, Luca</creatorcontrib><creatorcontrib>Dominietto, Alida</creatorcontrib><creatorcontrib>Finel, Herve</creatorcontrib><creatorcontrib>Chalandon, Yves</creatorcontrib><creatorcontrib>Kenzey, Chantal</creatorcontrib><creatorcontrib>Kharfan-Dabaja, Mohamed</creatorcontrib><creatorcontrib>Labussiere-Wallet, Helene</creatorcontrib><creatorcontrib>Moraleda, Jose M.</creatorcontrib><creatorcontrib>Pastano, Rocco</creatorcontrib><creatorcontrib>Perales, Miguel-Angel</creatorcontrib><creatorcontrib>El Ayoubi, Hanadi Rafii</creatorcontrib><creatorcontrib>Ruggeri, Annalisa</creatorcontrib><creatorcontrib>Sureda, Anna</creatorcontrib><creatorcontrib>Volt, Fernanda</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><creatorcontrib>Zhang, Mei-Jie</creatorcontrib><creatorcontrib>Gluckman, Eliane</creatorcontrib><creatorcontrib>Montoto, Silvia</creatorcontrib><creatorcontrib>Eapen, Mary</creatorcontrib><title>Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR</title><title>Journal of clinical oncology</title><addtitle>J CLIN ONCOL</addtitle><addtitle>J Clin Oncol</addtitle><description>PURPOSE To compare the outcomes of patients with Hodgkin or non-Hodgkin lymphoma undergoing nonmyeloablative haploidentical or unrelated cord blood (UCB) hematopoietic cell transplantation.
PATIENTS AND METHODS We retrospectively studied 740 patients with Hodgkin lymphoma (n = 283, 38%) and non-Hodgkin lymphoma (n = 457, 62%) age 18-75 years who received transplantations from 2009 to 2016. Data were reported to the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, Eurocord, or Center for International Blood and Marrow Transplant Research. Of the 526 patients who received haploidentical transplantation, 68% received bone marrow and 32% received peripheral blood. All patients received a uniform transplantation conditioning regimen (2 Gy of total-body irradiation, cyclophosphamide, and fludarabine) and graft-versus-host disease prophylaxis (calcineurin inhibitor and mycophenolate). In addition, patients who received a haploidentical transplantation received posttransplantation cyclophosphamide.
RESULTS Compared with haploidentical bone marrow and peripheral-blood transplantations and adjusted for age, lymphoma subtype, and disease status, survival was lower after UCB transplantation (hazard ratio [HR], 1.55; P = .001; and HR, 1.59; P = .005, respectively). Similarly, progression-free survival was lower after UCB transplantations compared with haploidentical bone marrow and peripheral-blood transplantations (HR, 1.44; P = .002; and HR, 1.86; P < .0001), respectively. The 4-year overall and progression-free survival rates after UCB transplantation were 49% and 36%, respectively, compared with 58% and 46% after haploidentical bone marrow transplantation and 59% and 52% after peripheral-blood transplantation, respectively. Lower survival was attributed to higher transplantation-related mortality after UCB transplantation compared with haploidentical bone marrow and peripheral-blood transplantation (HR, 1.91; P = .0001; and HR, 2.27; P = .0002, respectively).
CONCLUSION When considering HLA-mismatched transplantation for Hodgkin or non-Hodgkin lymphoma, the data support haploidentical related donor transplantation over UCB transplantation.</description><subject>Life Sciences & Biomedicine</subject><subject>Oncology</subject><subject>ORIGINAL REPORTS</subject><subject>Science & Technology</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><recordid>eNqNkc1v1DAQxS1ERZfCjTPKEYnNMrZjJ-aAVML2Ay0UoUVwsxzH6YYm9mInRXvjT6_btCu4cfL4-TdvbD-EXmBYYALw5mN5scBiASSD4hGaYUbyNM8Ze4xmkFOS4oL-OERPQ_gJgLOCsifokBKguMj5DP357Gy_M51TVaeG9tokx91gvJ3qD846n6y9smHbKTtE1dmkidqZqy-vWpsoWyfRIn3Yr3b9duN69TY58a5Pho1JVt-_pMv3n9bzZDl6p52v53dt5XkUvz5DB43qgnl-vx6hbyfLdXmWri5Oz8vjVaozBkOqoM4bTbkSwCpDK16bWmPDVKU15zUXtYgP5VjRAmcgMkpUrTihhBBBCgr0CL2bfLdj1cdeYwevOrn1ba_8TjrVyn9PbLuRl-5a5gRTJnA0eHVv4N2v0YRB9m3Qpov_YtwYJKGM8IyLjEV0PqHauxC8afZjMMjb0GQMTWIh70KL-Mu_r7aHH1KKwOsJ-G0q1wTdGqvNHgMARvOcF0WsgEa6-H-6bKdQSzfagd4Art6zsQ</recordid><startdate>20200510</startdate><enddate>20200510</enddate><creator>Fatobene, Giancarlo</creator><creator>Rocha, Vanderson</creator><creator>St Martin, Andrew</creator><creator>Hamadani, Mehdi</creator><creator>Robinson, Stephen</creator><creator>Bashey, Asad</creator><creator>Boumendil, Ariane</creator><creator>Brunstein, Claudio</creator><creator>Castagna, Luca</creator><creator>Dominietto, Alida</creator><creator>Finel, Herve</creator><creator>Chalandon, Yves</creator><creator>Kenzey, Chantal</creator><creator>Kharfan-Dabaja, Mohamed</creator><creator>Labussiere-Wallet, Helene</creator><creator>Moraleda, Jose M.</creator><creator>Pastano, Rocco</creator><creator>Perales, Miguel-Angel</creator><creator>El Ayoubi, Hanadi Rafii</creator><creator>Ruggeri, Annalisa</creator><creator>Sureda, Anna</creator><creator>Volt, Fernanda</creator><creator>Yakoub-Agha, Ibrahim</creator><creator>Zhang, Mei-Jie</creator><creator>Gluckman, Eliane</creator><creator>Montoto, Silvia</creator><creator>Eapen, Mary</creator><general>Amer Soc Clinical Oncology</general><general>American Society of Clinical Oncology</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2552-0542</orcidid><orcidid>https://orcid.org/0000-0002-6239-7387</orcidid><orcidid>https://orcid.org/0000-0002-3006-9725</orcidid></search><sort><creationdate>20200510</creationdate><title>Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR</title><author>Fatobene, Giancarlo ; Rocha, Vanderson ; St Martin, Andrew ; Hamadani, Mehdi ; Robinson, Stephen ; Bashey, Asad ; Boumendil, Ariane ; Brunstein, Claudio ; Castagna, Luca ; Dominietto, Alida ; Finel, Herve ; Chalandon, Yves ; Kenzey, Chantal ; Kharfan-Dabaja, Mohamed ; Labussiere-Wallet, Helene ; Moraleda, Jose M. ; Pastano, Rocco ; Perales, Miguel-Angel ; El Ayoubi, Hanadi Rafii ; Ruggeri, Annalisa ; Sureda, Anna ; Volt, Fernanda ; Yakoub-Agha, Ibrahim ; Zhang, Mei-Jie ; Gluckman, Eliane ; Montoto, Silvia ; Eapen, Mary</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-a0d7fc36a905be3b6dedc1e5abcc66d69d918361a381409432ada623222928303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Life Sciences & Biomedicine</topic><topic>Oncology</topic><topic>ORIGINAL REPORTS</topic><topic>Science & Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fatobene, Giancarlo</creatorcontrib><creatorcontrib>Rocha, Vanderson</creatorcontrib><creatorcontrib>St Martin, Andrew</creatorcontrib><creatorcontrib>Hamadani, Mehdi</creatorcontrib><creatorcontrib>Robinson, Stephen</creatorcontrib><creatorcontrib>Bashey, Asad</creatorcontrib><creatorcontrib>Boumendil, Ariane</creatorcontrib><creatorcontrib>Brunstein, Claudio</creatorcontrib><creatorcontrib>Castagna, Luca</creatorcontrib><creatorcontrib>Dominietto, Alida</creatorcontrib><creatorcontrib>Finel, Herve</creatorcontrib><creatorcontrib>Chalandon, Yves</creatorcontrib><creatorcontrib>Kenzey, Chantal</creatorcontrib><creatorcontrib>Kharfan-Dabaja, Mohamed</creatorcontrib><creatorcontrib>Labussiere-Wallet, Helene</creatorcontrib><creatorcontrib>Moraleda, Jose M.</creatorcontrib><creatorcontrib>Pastano, Rocco</creatorcontrib><creatorcontrib>Perales, Miguel-Angel</creatorcontrib><creatorcontrib>El Ayoubi, Hanadi Rafii</creatorcontrib><creatorcontrib>Ruggeri, Annalisa</creatorcontrib><creatorcontrib>Sureda, Anna</creatorcontrib><creatorcontrib>Volt, Fernanda</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><creatorcontrib>Zhang, Mei-Jie</creatorcontrib><creatorcontrib>Gluckman, Eliane</creatorcontrib><creatorcontrib>Montoto, Silvia</creatorcontrib><creatorcontrib>Eapen, Mary</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fatobene, Giancarlo</au><au>Rocha, Vanderson</au><au>St Martin, Andrew</au><au>Hamadani, Mehdi</au><au>Robinson, Stephen</au><au>Bashey, Asad</au><au>Boumendil, Ariane</au><au>Brunstein, Claudio</au><au>Castagna, Luca</au><au>Dominietto, Alida</au><au>Finel, Herve</au><au>Chalandon, Yves</au><au>Kenzey, Chantal</au><au>Kharfan-Dabaja, Mohamed</au><au>Labussiere-Wallet, Helene</au><au>Moraleda, Jose M.</au><au>Pastano, Rocco</au><au>Perales, Miguel-Angel</au><au>El Ayoubi, Hanadi Rafii</au><au>Ruggeri, Annalisa</au><au>Sureda, Anna</au><au>Volt, Fernanda</au><au>Yakoub-Agha, Ibrahim</au><au>Zhang, Mei-Jie</au><au>Gluckman, Eliane</au><au>Montoto, Silvia</au><au>Eapen, Mary</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR</atitle><jtitle>Journal of clinical oncology</jtitle><stitle>J CLIN ONCOL</stitle><addtitle>J Clin Oncol</addtitle><date>2020-05-10</date><risdate>2020</risdate><volume>38</volume><issue>14</issue><spage>1518</spage><epage>1526</epage><pages>1518-1526</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>PURPOSE To compare the outcomes of patients with Hodgkin or non-Hodgkin lymphoma undergoing nonmyeloablative haploidentical or unrelated cord blood (UCB) hematopoietic cell transplantation.
PATIENTS AND METHODS We retrospectively studied 740 patients with Hodgkin lymphoma (n = 283, 38%) and non-Hodgkin lymphoma (n = 457, 62%) age 18-75 years who received transplantations from 2009 to 2016. Data were reported to the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, Eurocord, or Center for International Blood and Marrow Transplant Research. Of the 526 patients who received haploidentical transplantation, 68% received bone marrow and 32% received peripheral blood. All patients received a uniform transplantation conditioning regimen (2 Gy of total-body irradiation, cyclophosphamide, and fludarabine) and graft-versus-host disease prophylaxis (calcineurin inhibitor and mycophenolate). In addition, patients who received a haploidentical transplantation received posttransplantation cyclophosphamide.
RESULTS Compared with haploidentical bone marrow and peripheral-blood transplantations and adjusted for age, lymphoma subtype, and disease status, survival was lower after UCB transplantation (hazard ratio [HR], 1.55; P = .001; and HR, 1.59; P = .005, respectively). Similarly, progression-free survival was lower after UCB transplantations compared with haploidentical bone marrow and peripheral-blood transplantations (HR, 1.44; P = .002; and HR, 1.86; P < .0001), respectively. The 4-year overall and progression-free survival rates after UCB transplantation were 49% and 36%, respectively, compared with 58% and 46% after haploidentical bone marrow transplantation and 59% and 52% after peripheral-blood transplantation, respectively. Lower survival was attributed to higher transplantation-related mortality after UCB transplantation compared with haploidentical bone marrow and peripheral-blood transplantation (HR, 1.91; P = .0001; and HR, 2.27; P = .0002, respectively).
CONCLUSION When considering HLA-mismatched transplantation for Hodgkin or non-Hodgkin lymphoma, the data support haploidentical related donor transplantation over UCB transplantation.</abstract><cop>ALEXANDRIA</cop><pub>Amer Soc Clinical Oncology</pub><pmid>32031876</pmid><doi>10.1200/JCO.19.02408</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-2552-0542</orcidid><orcidid>https://orcid.org/0000-0002-6239-7387</orcidid><orcidid>https://orcid.org/0000-0002-3006-9725</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2020-05, Vol.38 (14), p.1518-1526 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_webofscience_primary_000537768800003CitationCount |
| source | American Society of Clinical Oncology Online Journals; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Life Sciences & Biomedicine Oncology ORIGINAL REPORTS Science & Technology |
| title | Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T15%3A46%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nonmyeloablative%20Alternative%20Donor%20Transplantation%20for%20Hodgkin%20and%20Non-Hodgkin%20Lymphoma:%20From%20the%20LWP-EBMT,%20Eurocord,%20and%20CIBMTR&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=Fatobene,%20Giancarlo&rft.date=2020-05-10&rft.volume=38&rft.issue=14&rft.spage=1518&rft.epage=1526&rft.pages=1518-1526&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.19.02408&rft_dat=%3Cproquest_webof%3E2352646945%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2352646945&rft_id=info:pmid/32031876&rfr_iscdi=true |